{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:39:23Z","timestamp":1784302763416,"version":"3.55.0"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sialorrhea (drooling) is a common symptom of Parkinson's disease (PD) that can significantly impair a patient's health and quality of life. Fifty\u2010four PD subjects with troublesome sialorrhea were enrolled using a multicenter, randomized, double\u2010blind, sequential\u2010dose escalation design in which subjects received a single intraglandular treatment with botulinum toxin type B (doses of 1,500 Units [0.3 mL]; 2,500 Units [0.5 ml]; or 3,500 Units [0.7 ml]) or placebo. Postinjection, subjects were followed acutely for 4 weeks and long\u2010term for up to 20 weeks. Safety\/tolerability, as assessed by adverse events, was the primary outcome measure. Efficacy, as assessed by the Drooling Frequency and Severity Scale and unstimulated salivary flow rate, was secondary. Gastrointestinal\u2010related adverse events occurred more frequently in the active groups versus placebo group (31% vs 7%), with dry mouth being most common (15%). There were no serious adverse events attributed to botulinum toxin type B or discontinuations due to adverse events from treatment. At 4 weeks postinjection, Drooling Frequency and Severity Scale scores significantly improved versus placebo (\u22121.3 \u00b1 1.3) in a dose\u2010related manner (\u22122.1 \u00b1 1.2, <jats:italic>P<\/jats:italic> = 0.0191; \u22123.3 \u00b1 1.4, <jats:italic>P<\/jats:italic> &lt; 0.0001; \u22123.5 \u00b1 1.1, <jats:italic>P<\/jats:italic> &lt; 0.0001, respectively) and unstimulated salivary flow rates significantly decreased in all active groups versus placebo (<jats:italic>P<\/jats:italic> \u2264 0.0009). Furthermore, treated subjects appeared to have more sustained improvement in sialorrhea than placebo subjects. We conclude that intraglandular injection of botulinum toxin type B was safe, tolerable, and efficacious in treating sialorrhea in PD patients. Additional studies are warranted to further confirm the drug's robust efficacy, as well as evaluate its effect with repeated dosing. \u00a9 2011 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.23929","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T17:16:40Z","timestamp":1314897400000},"page":"219-226","source":"Crossref","is-referenced-by-count":87,"title":["Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: A prospective double\u2010blind trial"],"prefix":"10.1002","volume":"27","author":[{"given":"Robert","family":"Chinnapongse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Gullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2001.00328.x"},{"key":"e_1_2_7_3_2","first-page":"13","article-title":"Salivary symptoms in Parkinson's disease","volume":"14","author":"Bateson MC","year":"1973","journal-title":"Arch Neurol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21752"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H381"},{"key":"e_1_2_7_6_2","first-page":"2628","article-title":"Sialorrhea: a management challenge","volume":"69","author":"Hockstein NG","year":"2004","journal-title":"Am Fam Physician"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.9.1551"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000183055.81056.5c"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21724"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000174433.76707.8c"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000101713.81253.4C"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.05.005"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10484"},{"key":"e_1_2_7_14_2","first-page":"23","article-title":"Botulinum toxin for the treatment of parkinsonian sialorrhea","volume":"35","author":"Friedman A","year":"2001","journal-title":"Neurol Neurochir Pol"},{"key":"e_1_2_7_15_2","first-page":"3","article-title":"Teoria statistica delle classi e calcolo delle probabilit?","volume":"8","author":"Bonferroni CE","year":"1936","journal-title":"Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22260"},{"key":"e_1_2_7_17_2","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_7_18_2","first-page":"153","volume-title":"Recent developments in Parkinsons disease","author":"Fahn S","year":"1987"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_2_7_20_2","volume-title":"Myobloc\u00ae (rimabotulinumtoxinB) Injection [package insert]","year":"2010"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01447.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-0085-1"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23929","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.23929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:15:08Z","timestamp":1760966108000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.23929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1002\/mds.23929"],"URL":"https:\/\/doi.org\/10.1002\/mds.23929","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}